Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAXrelief is an over-the-counter (OTC) combination analgesic medication marketed by Akron Pharma. It is formulated with a combination of acetaminophen, aspirin, and caffeine, which is a standard regimen for the treatment of migraines and tension headaches. Acetaminophen serves as a non-aspirin pain reliever and antipyretic, while aspirin acts as a nonsteroidal anti-inflammatory drug (NSAID) by irreversibly inhibiting cyclooxygenase enzymes to reduce prostaglandin synthesis. Caffeine is included as an analgesic adjuvant, enhancing the efficacy of the pain relievers through adenosine receptor antagonism and cerebral vasoconstriction. The product is indicated for the temporary relief of minor aches and pains associated with headaches, migraines, the common cold, arthritis, muscular aches, sinusitis, and toothaches.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MAXrelief.